April 23, 2019
Nippon Kayaku said on April 22 that it has been granted exclusive rights in Japan to manufacture and commercialize Eli Lilly’s soon-to-be-approved lung cancer treatment necitumumab, an EGFR antagonist also known as Portrazza overseas. Necitumumab is a recombinant human IgG1...read more